Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies.

cancer stem cell epithelial-mesenchymal transition microRNA nanomedicine signaling pathway

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2020
Historique:
received: 09 04 2020
accepted: 03 06 2020
entrez: 7 7 2020
pubmed: 7 7 2020
medline: 7 7 2020
Statut: epublish

Résumé

The mechanism of epithelial-mesenchymal transition (EMT) consists of the cellular phenotypic transition from epithelial to mesenchymal status. The cells exhibiting EMT exist in cancer stem cell (CSC) population, which is involved in drug resistance. CSCs demonstrating EMT feature remain after cancer treatment, which leads to drug resistance, recurrence, metastasis and malignancy of cancer. In this context, the recent advance of nanotechnology in the medical application has ascended the possibility to target CSCs using nanomedicines. In this review article, we focused on the mechanism of CSCs and EMT, especially into the signaling pathways in EMT, regulation of EMT and CSCs by microRNAs and nanomedicine-based approaches to target CSCs.

Identifiants

DOI: 10.3389/fphar.2020.00904 PMID: 32625096 PMC: PMC7311659
pubmed: 32625096
doi: 10.3389/fphar.2020.00904
pmc: PMC7311659
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

904

Informations de copyright

Copyright © 2020 Tanabe, Quader, Cabral and Ono.

Références

World J Stem Cells. 2015 Aug 26;7(7):992-8
pubmed: 26328015
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Cell Death Dis. 2019 Feb 27;10(3):205
pubmed: 30814494
Cell Stem Cell. 2019 Jan 3;24(1):25-40
pubmed: 30595497
Oncotarget. 2016 Nov 1;7(44):71362-71377
pubmed: 27655685
Stem Cells Int. 2017;2017:2925869
pubmed: 28356914
Adv Sci (Weinh). 2019 Mar 07;6(9):1801885
pubmed: 31065520
Nanomedicine (Lond). 2019 Sep;14(18):2487-2514
pubmed: 31490100
BMC Immunol. 2015 Jan 31;16:1
pubmed: 25636521
Elife. 2017 Dec 05;6:
pubmed: 29206104
Stem Cells. 2016 Aug;34(8):1997-2007
pubmed: 27251010
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
Cancer Res. 2006 Mar 1;66(5):2725-31
pubmed: 16510593
Cell Death Dis. 2018 Jul 24;9(8):807
pubmed: 30042387
Int J Oncol. 2014 Jun;44(6):1955-70
pubmed: 24728500
Theranostics. 2020 Jan 1;10(3):1181-1196
pubmed: 31938059
Sci Rep. 2017 Jun 6;7(1):2851
pubmed: 28588211
Chem Rev. 2018 Jul 25;118(14):6844-6892
pubmed: 29957926
J Hematol Oncol. 2017 Mar 29;10(1):79
pubmed: 28356122
Biomed Pharmacother. 2019 Feb;110:803-817
pubmed: 30554119
Stem Cells Transl Med. 2019 Jan;8(1):75-81
pubmed: 30328686
Am J Cancer Res. 2015 Feb 15;5(3):945-55
pubmed: 26045979
BMC Syst Biol. 2013 Sep 04;7:86
pubmed: 24006872
J Control Release. 2016 May 28;230:26-33
pubmed: 27040816
Cancer Lett. 2014 Sep 1;351(2):173-81
pubmed: 24952258
Oncoimmunology. 2017 Oct 11;7(2):e1380765
pubmed: 29416940
Oncology (Williston Park). 2014 Dec;28(12):1101-7, 1110
pubmed: 25510809
Cancer Chemother Pharmacol. 2017 Feb;79(2):295-301
pubmed: 27942929
Expert Rev Clin Pharmacol. 2018 Jun;11(6):599-610
pubmed: 29768060
Oncoscience. 2015 Aug 31;2(10):841-2
pubmed: 26682272
Mol Cell Biol. 2009 Nov;29(21):5923-40
pubmed: 19703993
Exp Hematol. 2017 Aug;52:12-23
pubmed: 28456748
Int J Pharm. 2018 Apr 5;540(1-2):132-149
pubmed: 29427746
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1397-402
pubmed: 21220315
Cancer Sci. 2019 Aug;110(8):2590-2599
pubmed: 31169336
Cold Spring Harb Symp Quant Biol. 2016;81:11-19
pubmed: 28057845
World J Stem Cells. 2015 Jan 26;7(1):208-22
pubmed: 25621121
Arch Toxicol. 2017 Feb;91(2):605-619
pubmed: 28032148
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Mol Cancer Ther. 2008 Apr;7(4):829-40
pubmed: 18413796
Cancer Sci. 2011 Jun;102(6):1193-200
pubmed: 21366804
Nat Cell Biol. 2017 May;19(5):518-529
pubmed: 28414315
PLoS One. 2013 May 14;8(5):e62757
pubmed: 23690952
BMC Cancer. 2016 Nov 21;16(1):906
pubmed: 27871274
EMBO Mol Med. 2012 Mar;4(3):143-59
pubmed: 22351564
Clin Transl Med. 2017 Dec 11;6(1):44
pubmed: 29230567
Nat Rev Cancer. 2008 Oct;8(10):755-68
pubmed: 18784658
J Cell Biol. 2007 Jul 30;178(3):425-36
pubmed: 17664334
Cancer Metastasis Rev. 2012 Dec;31(3-4):653-62
pubmed: 22684369
Asian Pac J Cancer Prev. 2019 Jun 01;20(6):1895-1900
pubmed: 31244315
Pharmacol Ther. 2018 Jul;187:13-30
pubmed: 29421575
Am J Pathol. 2003 Oct;163(4):1437-47
pubmed: 14507651
Int J Mol Sci. 2018 Nov 20;19(11):
pubmed: 30463358
Oncogene. 2010 Dec 9;29(49):6485-98
pubmed: 20802523
Cancer Chemother Pharmacol. 2017 Oct;80(4):765-775
pubmed: 28887583
Int J Mol Sci. 2017 Nov 08;18(11):
pubmed: 29117122
Nature. 2015 Nov 26;527(7579):472-6
pubmed: 26560033
World J Stem Cells. 2015 Apr 26;7(3):535-40
pubmed: 25914760
Cancer Cell. 2012 Mar 20;21(3):283-96
pubmed: 22439924
Cancer Res. 2006 Apr 1;66(7):3567-75
pubmed: 16585181
Acta Biochim Biophys Sin (Shanghai). 2018 Jan 1;50(1):91-97
pubmed: 29069287
Oncotarget. 2011 Dec;2(12):896-917
pubmed: 22203527
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Oncotarget. 2016 Nov 15;7(46):76337-76353
pubmed: 27486983
Tumour Biol. 2016 Jun;37(6):8327-35
pubmed: 26729198
Cancers (Basel). 2019 Jun 17;11(6):
pubmed: 31213009
Sci Rep. 2017 Jun 21;7(1):4002
pubmed: 28638102
Cell Stem Cell. 2015 Mar 5;16(3):225-38
pubmed: 25748930
Cancers (Basel). 2019 Mar 05;11(3):
pubmed: 30841635
J Control Release. 2014 Sep 28;190:465-76
pubmed: 24993430
Semin Cancer Biol. 2018 Dec;53:156-167
pubmed: 30471331
Oncotarget. 2018 Nov 2;9(86):35705-35716
pubmed: 30479699
Oncotarget. 2017 May 23;8(21):35376-35389
pubmed: 28430640
Cancer Res. 2011 Feb 1;71(3):634-9
pubmed: 21266356
Nat Cell Biol. 2008 May;10(5):593-601
pubmed: 18376396
Oncol Rep. 2010 Dec;24(6):1637-43
pubmed: 21042762
Int J Mol Sci. 2016 Nov 26;17(12):
pubmed: 27898034
J Clin Med. 2016 Mar 28;5(4):
pubmed: 27043642
Nat Cell Biol. 2008 Mar;10(3):295-305
pubmed: 18297062
EMBO J. 2008 Feb 6;27(3):471-81
pubmed: 18256698
Science. 2016 Mar 4;351(6277):aad3680
pubmed: 26941323
Stem Cells Transl Med. 2015 Sep;4(9):1033-43
pubmed: 26136504
NPJ Breast Cancer. 2017 Apr 19;3:14
pubmed: 28649654
BMC Cancer. 2017 Aug 29;17(1):583
pubmed: 28851312
Cell Mol Life Sci. 2017 Nov;74(22):4121-4132
pubmed: 28623509
Stem Cell Res. 2016 Mar;16(2):405-17
pubmed: 26926234
Nature. 2013 Sep 19;501(7467):328-37
pubmed: 24048065
PLoS One. 2014 Mar 11;9(3):e90353
pubmed: 24618589

Auteurs

Shihori Tanabe (S)

Division of Risk Assessment, Center for Biological Safety and Research (CBSR), National Institute of Health Science (NIHS), Kawasaki, Japan.

Sabina Quader (S)

Innovation Centre of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, Kawasaki, Japan.

Horacio Cabral (H)

Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.

Ryuichi Ono (R)

Division of Cellular and Molecular Toxicology, Center for Biological Safety and Research (CBSR), National Institute of Health Science (NIHS), Kawasaki, Japan.

Classifications MeSH